1. Wu, Bingbing, Song, Mei, Dong, Qun, Ma, Xiaojing, Wei, Fang. 2022. UBR5 promotes tumor immune evasion through enhancing IFN-γ-induced PDL1 transcription in triple negative breast cancer. In Theranostics, 12, 5086-5102. doi:10.7150/thno.74989. https://pubmed.ncbi.nlm.nih.gov/35836797/
2. Song, Mei, Yeku, Oladapo O, Rafiq, Sarwish, Brentjens, Renier J, Ma, Xiaojing. 2020. Tumor derived UBR5 promotes ovarian cancer growth and metastasis through inducing immunosuppressive macrophages. In Nature communications, 11, 6298. doi:10.1038/s41467-020-20140-0. https://pubmed.ncbi.nlm.nih.gov/33293516/
3. Yang, Duomeng, Geng, Tingting, Harrison, Andrew G, Wang, Yanlin, Wang, Penghua. 2024. UBR5 promotes antiviral immunity by disengaging the transcriptional brake on RIG-I like receptors. In Nature communications, 15, 780. doi:10.1038/s41467-024-45141-1. https://pubmed.ncbi.nlm.nih.gov/38278841/
4. Huo, Qi, Hu, Junjie, Hou, Binfen, Du, Yulin, Li, Yao. 2022. Clinicopathological Features and Prognostic Evaluation of UBR5 in Liver Cancer Patients. In Pathology oncology research : POR, 28, 1610396. doi:10.3389/pore.2022.1610396. https://pubmed.ncbi.nlm.nih.gov/36388433/
5. Deng, Ling, Liao, Li, Zhang, Yin-Ling, Shao, Zhi-Ming, Li, Da-Qiang. 2024. SF3A2 promotes progression and cisplatin resistance in triple-negative breast cancer via alternative splicing of MKRN1. In Science advances, 10, eadj4009. doi:10.1126/sciadv.adj4009. https://pubmed.ncbi.nlm.nih.gov/38569025/
6. Song, Mei, Huang, Shuting, Wu, Xiaoxue, Ma, Xiaojing, He, Weiling. 2024. UBR5 mediates colorectal cancer chemoresistance by attenuating ferroptosis via Lys 11 ubiquitin-dependent stabilization of Smad3-SLC7A11 signaling. In Redox biology, 76, 103349. doi:10.1016/j.redox.2024.103349. https://pubmed.ncbi.nlm.nih.gov/39260061/
智鼠故事 
